RT @DrewMoghanaki: New data from the VA demonstrate "Some Durva" is better than "No Durva" for all comers after CRT for stage III NSCLC. Ho…
RT @DrewMoghanaki: New data from the VA demonstrate "Some Durva" is better than "No Durva" for all comers after CRT for stage III NSCLC. Ho…
RT @DrewMoghanaki: New data from the VA demonstrate "Some Durva" is better than "No Durva" for all comers after CRT for stage III NSCLC. Ho…
RT @drvineetgovinda: Very relevant for India @SACCConsortium @IJMPOofficial @Amolpatel_dr @DrBivas Combine with low dose IO - route to affo…
Pro tip: an inverse relationship between Treatment Duration & OS is almost never seen in retrospective studies due to immortal time bias. These VA data suggest checkpoint inhibition may be even more effective if we pulsed it’s delivery. @RamalingamMD @
RT @drvineetgovinda: Very relevant for India @SACCConsortium @IJMPOofficial @Amolpatel_dr @DrBivas Combine with low dose IO - route to affo…
Very relevant for India @SACCConsortium @IJMPOofficial @Amolpatel_dr @DrBivas Combine with low dose IO - route to affordability in adjuvant stage 3 NSCLC?
RT @oncologician: Maybe 12 months of adjuvant Durvalumab after CRT is not necessary in StgIII NSCLC
RT @DrewMoghanaki: New data from the VA demonstrate "Some Durva" is better than "No Durva" for all comers after CRT for stage III NSCLC. Ho…
Maybe 12 months of adjuvant Durvalumab after CRT is not necessary in StgIII NSCLC
RT @DrewMoghanaki: New data from the VA demonstrate "Some Durva" is better than "No Durva" for all comers after CRT for stage III NSCLC. Ho…
RT @DrewMoghanaki: New data from the VA demonstrate "Some Durva" is better than "No Durva" for all comers after CRT for stage III NSCLC. Ho…
RT @DrewMoghanaki: New data from the VA demonstrate "Some Durva" is better than "No Durva" for all comers after CRT for stage III NSCLC. Ho…
RT @finn_corinne: Great to see real world data on the use of durvalumab but the conclusion is an overstatement in my view. If PACIFIC inclu…
RT @finn_corinne: Great to see real world data on the use of durvalumab but the conclusion is an overstatement in my view. If PACIFIC inclu…
RT @finn_corinne: Great to see real world data on the use of durvalumab but the conclusion is an overstatement in my view. If PACIFIC inclu…
RT @finn_corinne: Great to see real world data on the use of durvalumab but the conclusion is an overstatement in my view. If PACIFIC inclu…
RT @finn_corinne: Great to see real world data on the use of durvalumab but the conclusion is an overstatement in my view. If PACIFIC inclu…
Great to see real world data on the use of durvalumab but the conclusion is an overstatement in my view. If PACIFIC inclusion criteria are used, patients selected on the basis of response to CTRT, fitness and resolution of CTRT side effects. Stage migratio
RT @DrewMoghanaki: New data from the VA demonstrate "Some Durva" is better than "No Durva" for all comers after CRT for stage III NSCLC. Ho…
RT @DrewMoghanaki: New data from the VA demonstrate "Some Durva" is better than "No Durva" for all comers after CRT for stage III NSCLC. Ho…
RT @DrewMoghanaki: New data from the VA demonstrate "Some Durva" is better than "No Durva" for all comers after CRT for stage III NSCLC. Ho…
RT @DrewMoghanaki: New data from the VA demonstrate "Some Durva" is better than "No Durva" for all comers after CRT for stage III NSCLC. Ho…
New data from the VA demonstrate "Some Durva" is better than "No Durva" for all comers after CRT for stage III NSCLC. However, 12 months may be unnecessary. @max_diehn #ASCO21 #lcsm #radonc https://t.co/okZW8w9O6M https://t.co/havx8YFvHI